Adma Biologics (ADMA) Stock Price, Quote & News

Company Profile

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the tre...

Industry: Biotechnology

Sector: Healthcare

Phone: 201 478 5552

Fax: 201 478 5553

Website: www.admabiologics.com

Address:

465 State Route 17, Ramsey, United States

BeefStewart Aug. 8 at 7:42 PM

$ADMA Does anyone have any comment on this post? It reads as very optimistic/ambitious; but it may prove accurate as well, if the stars align. Might ADMA start to appreciate between now and next quarter? At around $10, it seems that there is still considerable doubt baked into the price.

0 · Reply

SuperGreenToday Aug. 7 at 9:29 PM

$ADMA Share Price: $9.88 Contract Selected: Jan 15, 2027 $10 Calls Buy Zone: $1.27 – $1.58 Target Zone: $2.10 – $2.57 Potential Upside: 56% ROI Time to Expiration: 160 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

DarthWallstreet Aug. 7 at 9:09 PM

$ADMA Thought for sure this was gonna continue going up today, maybe some profit taking? Currently no position.

1 · Reply

ThommyBuy Aug. 7 at 6:43 PM

$ADMA after clicking the link there is an ad to gain access for 1 hour. do NOT click on that link!!! There is a BULLSHIT virus popup that will launch

1 · Reply

Merlintrader Aug. 7 at 6:35 PM

$ADMA: Can the Buyback Rewrite the Valuation Math? 11 Questions Investors Are Asking After Q2 https://www.merlintrader.com/adma-investors-questions/

1 · Reply

BullMaven Aug. 7 at 5:06 PM

$ADMA adding 500

0 · Reply

Alon_R Aug. 7 at 4:54 PM

$ADMA Good to see the reduction in shares outstanding reflected on the screens. These are two screenshots put together, one from yesterday and one from today. One can notice the reduction of 8 million shares outstanding. I like the strategy of CEO Adam Grossman: -> Let's rapidly grow ASCENIV (high margins). -> Let's buy back as many outstanding shares as possible, because we are very profitable (cash cow). -> When SG-001 joins the already gigantic ASCENIV, with already dozens of millions fewer shares outstanding, we will very possibly be around a three-digit valuation at that stage.

0 · Reply

De12 Aug. 7 at 4:53 PM

$ADMA Buyout incoming!

0 · Reply

BeefStewart Aug. 7 at 4:50 PM

$ADMA Can anyone give me a sober-minded, grounded take on expectations going forward? I didn't listen to the call this time, and... I've been hurt before! 🥺

1 · Reply

LHBhandy Aug. 7 at 4:18 PM

$ADMA Keep on buying Adam!!!! In the end, we’ll be well rewarded for putting up with the BS “short attack” from Culper and the 24, 000,000 shares shorted!!! Help them get covered Adam @ a hefty premium!!! Extremely

0 · Reply

Adma Biologics reports Q2 EPS 16c, consensus 16c

2026-08-05T21:01:11.000Z - 4 days ago

Adma Biologics backs FY26 revenue view $530M-$560M, consensus $534.37M

Aug 5, 2026, 4:30 PM EDT - 4 days ago

ADMA Biologics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 4 days ago

ADMA Biologics Earnings release: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 4 days ago

ADMA Biologics Quarterly report: Q2 2026

Aug 5, 2026, 4:05 PM EDT - 4 days ago

ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update

Jul 31, 2026, 1:20 PM EDT - 9 days ago

ADMA Biologics (NASDAQ: ADMA) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.

Jul 30, 2026, 10:07 AM EDT - 10 days ago

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 10, 2026 in ADMA BIOLOGICS, INC. Lawsuit - ADMA

Jul 29, 2026, 7:00 AM EDT - 11 days ago

ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026

Jul 27, 2026, 10:00 AM EDT - 13 days ago

Did You Lose Money Investing in ADMA Biologics, Inc. (ADMA)? Contact Robbins LLP for Information About Recovering Your Losses

Jul 24, 2026, 6:34 AM EDT - 16 days ago

$ADMA Fraud Notification: ADMA Biologics Sued for Fraud Over Misrepresentations about Channel Stuffing – Investors Notified to Contact BFA Law

2026-07-15T11:25:44.000Z - 25 days ago

Adma Biologics price target lowered to $17 from $20 at Mizuho

Jul 6, 2026, 6:48 AM EDT - 4 weeks ago

$ADMA Fraud Notification: ADMA Biologics Sued for Securities Fraud After Channel Stuffing Claims Spark a 29% Stock Drop – Investors Notified to Contact BFA Law by August 10

Jul 2, 2026, 7:00 PM EDT - 5 weeks ago

ADMA INVESTOR REMINDER: ADMA Biologics, Inc. Investors Have Until August 10, 2026 To Seek Lead Plaintiff Role

Jun 24, 2026, 9:24 AM EDT - 6 weeks ago

ADMA BIOLOGICS, INC. (ADMA) INVESTOR ALERT Investors With Large Losses in ADMA Biologics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Jun 23, 2026, 7:55 AM EDT - 6 weeks ago

Grabar Law Office Investigates ADMA Biologics, Inc. (ADMA) on Behalf of Long-Term Shareholders

Jun 15, 2026, 10:53 AM EDT - 7 weeks ago

20 growth stocks priced as value stocks

AMG ANIP ARR BILL CG DAN EFC

Jun 11, 2026, 1:33 PM EDT - 2 months ago

$ADMA Breaking News: ADMA Biologics Sued for Securities Fraud after Channel Stuffing Claims Lead to 16% Stock Drop – Investors Notified to Contact BFA Law

2026-06-10T11:40:39.000Z - 2 months ago

Adma Biologics resumed with an Outperform at Raymond James

Jun 10, 2026, 6:41 AM EDT - 2 months ago

ADMA Biologics Investigation: ADMA Biologics (ADMA) Investigated for Alleged Channel Stuffing – Contact BFA Law if You Suffered Losses

Jun 3, 2026, 6:07 AM EDT - 2 months ago

ADMA Legal Claims: ADMA Biologics may have Misrepresented its Revenue Sources to Investors – Contact BFA Law about its Pending Securities Fraud Investigation

Jun 2, 2026, 10:00 AM EDT - 2 months ago

ADMA Biologics Transcript: AGM 2026

May 29, 2026, 6:33 AM EDT - 2 months ago

$ADMA Securities News: ADMA Biologics Investigated for Securities Fraud Over Channel Stuffing Allegations – Investors with Losses Notified to Contact BFA Law

May 25, 2026, 7:18 AM EDT - 2 months ago

$ADMA Shareholder Announcement: ADMA Biologics may have Misled Investors about its Revenue – Contact BFA Law about its Pending Investigation

May 22, 2026, 6:43 AM EDT - 2 months ago

ADMA Inquiry News: ADMA Biologics Investors are Notified of BFA Law's Ongoing Investigation into the Company's Potential Misstatements – Contact the Firm if You Lost Money

May 20, 2026, 6:20 AM EDT - 2 months ago

ADMA Securities Investigation: ADMA Biologics 29% Stock Drop Triggers Securities Fraud Investigation Over Channel Stuffing Claims – Investors Urged to Contact BFA Law

May 18, 2026, 6:07 AM EDT - 2 months ago

ADMA Fraud Notice: ADMA Biologics is being Investigated for Securities Fraud after 29% Stock Drop -- Investors Reminded to Contact BFA Law

May 15, 2026, 6:33 AM EDT - 3 months ago

ADMA Shareholder News: ADMA Biologics Investigated for Securities Fraud Over Alleged Misrepresentations about Channel Stuffing – Investors Notified to Contact BFA Law

May 11, 2026, 6:15 AM EDT - 3 months ago

$ADMA Investigation Reminder: ADMA Biologics Investigation on behalf of Investors is Ongoing – Contact BFA Law if You Lost Money

May 8, 2026, 6:07 AM EDT - 3 months ago

$ADMA Investor News: ADMA Biologics Stock Drops 29% Amid Channel Stuffing Claims Triggering Securities Fraud Investigation – Contact BFA Law if You Suffered Losses

2026-05-07T16:02:55.000Z - 3 months ago

Adma Biologics price target lowered to $20 from $24 at Mizuho

May 7, 2026, 9:16 AM EDT - 3 months ago

ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors

2026-05-07T10:48:12.000Z - 3 months ago

Adma Biologics price target lowered to $18 from $21 at Canaccord

2026-05-07T00:37:49.000Z - 3 months ago

Adma Biologics reports Q1 EPS 19c, consensus 20c

2026-05-07T00:36:02.000Z - 3 months ago

Adma Biologics sees FY26 revenue $530M-$560M, consensus $629.1M

May 6, 2026, 4:30 PM EDT - 3 months ago

ADMA Biologics Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

ADMA Biologics Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

ADMA Biologics Quarterly report: Q1 2026

May 6, 2026, 4:05 PM EDT - 3 months ago

ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update

May 6, 2026, 6:41 AM EDT - 3 months ago

$ADMA Shareholder News: ADMA Biologics 29% Stock Drop Leads to Securities Fraud Investigation – BFA Law Encourages Investors with Losses to Act

2026-05-04T11:31:54.000Z - 3 months ago

Adma Biologics announces FDA approval for Asceniv sBLA

May 4, 2026, 7:00 AM EDT - 3 months ago

ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older

May 1, 2026, 6:16 AM EDT - 3 months ago

Investor Notice: ADMA Biologics (NASDAQ:ADMA) may have Committed Securities Fraud after Channel Stuffing Claims Disclosed – Contact BFA Law about the Pending Investigation

Apr 29, 2026, 7:00 AM EDT - 3 months ago

ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026

Apr 29, 2026, 6:41 AM EDT - 3 months ago

$ADMA Fraud: ADMA Biologics Channel Stuffing Claims Trigger Securities Investigation – Investors Alerted to Contact BFA Law

Apr 27, 2026, 6:38 AM EDT - 3 months ago

ADMA Stock: ADMA Biologics Securities Fraud Investigation is Ongoing – Investors with Losses Urged to Contact BFA Law

Apr 22, 2026, 6:05 AM EDT - 3 months ago

$ADMA Investigation: BFA Law Notifies ADMA Biologics Investors that Lost Money after 29% Stock Drop of Ongoing Securities Fraud Investigation

2026-04-21T09:25:41.000Z - 3 months ago

Adma Biologics initiated with a Buy at Canaccord

2026-04-20T20:45:12.000Z - 3 months ago

Adma Biologics initiated with a Buy at Canaccord

Apr 15, 2026, 8:00 AM EDT - 4 months ago

ADMA Biologics Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 4 months ago

ADMA Biologics Proxy statement: Proxy filing

2026-04-13T14:43:12.000Z - 4 months ago

Adma Biologics price target lowered to $24 from $30 at Mizuho

2026-03-27T11:42:03.000Z - 4 months ago

Adma Biologics responds to short seller report by Culper Research

2026-03-26T16:06:09.000Z - 4 months ago

Adma Biologics falls -15.9%

2026-03-26T14:07:02.000Z - 4 months ago

Adma Biologics falls -19.9%

2026-03-26T08:50:09.000Z - 4 months ago

Cantor downgrades Adma Biologics on lack of clarity post short report

2026-03-25T23:25:28.000Z - 4 months ago

Adma Biologics says Culper report contains ‘inaccurate statements’

BeefStewart Aug. 8 at 7:42 PM

0 · Reply

SuperGreenToday Aug. 7 at 9:29 PM

0 · Reply

DarthWallstreet Aug. 7 at 9:09 PM

$ADMA Thought for sure this was gonna continue going up today, maybe some profit taking? Currently no position.

1 · Reply

ThommyBuy Aug. 7 at 6:43 PM

$ADMA after clicking the link there is an ad to gain access for 1 hour. do NOT click on that link!!! There is a BULLSHIT virus popup that will launch

1 · Reply

Merlintrader Aug. 7 at 6:35 PM

$ADMA: Can the Buyback Rewrite the Valuation Math? 11 Questions Investors Are Asking After Q2 https://www.merlintrader.com/adma-investors-questions/

1 · Reply

BullMaven Aug. 7 at 5:06 PM

$ADMA adding 500

0 · Reply

Alon_R Aug. 7 at 4:54 PM

0 · Reply

De12 Aug. 7 at 4:53 PM

$ADMA Buyout incoming!

0 · Reply

BeefStewart Aug. 7 at 4:50 PM

$ADMA Can anyone give me a sober-minded, grounded take on expectations going forward? I didn't listen to the call this time, and... I've been hurt before! 🥺

1 · Reply

LHBhandy Aug. 7 at 4:18 PM

0 · Reply

USMAgrad Aug. 7 at 2:17 PM

$ADMA Woohoo! Back over $10🙌🏻 I sold my shares last week to buy more $IOVA but I’m super happy for those who are still invested here - this never EVER should have been below $10… GLTA🙌🏻🫶🏻

0 · Reply

Alon_R Aug. 7 at 2:00 PM

$ADMA Strong buyback policy. The strategy is clear-> Most likely, in a few years, ADMA will have a gigantic ASCENIV franchise with very strong margins, plus SG-001, which has the potential to become also ASCENIV-caliber premium franchise, along with many dozens of millions fewer shares outstanding. At that point, a three-digit valuation seems plausible. That's the opportunity.

0 · Reply

WvKNL Aug. 7 at 1:46 PM

$ADMA Good!

0 · Reply

Stoxx4fun Aug. 7 at 12:56 PM

$ADMA State Street Corp ownership in ADMA / ADMA Biologics, Inc. 2026-08-07 - State Street Corp has filed an SCHEDULE 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 17,116,022 shares of ADMA Biologics, Inc. (US:ADMA). This represents 7.4 percent ownership of the company. In their previous filing dated 2025-08-11 , State Street Corp had reported owning 12,078,505 shares, indicating an increase of 41.71 percent.

1 · Reply

SuperGreenToday Aug. 6 at 9:14 PM

$ADMA Share Price: $10.06 Contract Selected: Jan 15, 2027 $10 Calls Buy Zone: $1.36 – $1.68 Target Zone: $2.38 – $2.91 Potential Upside: 65% ROI Time to Expiration: 161 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Mr_Maniacal Aug. 6 at 8:58 PM

$ADMA For those that have been here here a minute... remember the euphoria that happened when the yield enhancement was approved? We spiked into the mid 20s. Now, I am not making a case for that valuation level... but since that time the ONLY thing that has fundamentally changed are the pressures on Bivigam... which has not been the focus of growth for this company. Yes, we were hit by a short report which weakened investor confidence... thus a temporary multiple reduction until additional proof contradicts. Meanwhile management has done (and continues to do) what management should be doing, and the underlying business remains very largely as it has been.

1 · Reply

oldhockeyplayerwithteeth Aug. 6 at 8:26 PM

$ADMA Disciplined Capital Allocation Continues to Enhance Stockholder Value. During the second quarter, ADMA repurchased approximately 7.1 million shares of common stock under its previously authorized share repurchase program. Year-to-date total stock repurchases through June 30, 2026 were approximately 13.8 million shares, amounting to 5.3% of the Company’s common stock outstanding. In addition to the Company’s accelerated share repurchase (ASR) program completed in the second quarter, ADMA’s stock repurchases were funded through organically generated operating cash flow, while the Company maintained substantial financial flexibility to support commercial expansion, manufacturing initiatives and pipeline development. The Company remains active with share repurchases and is on track to complete its previously stated $200 million or more 2026 share repurchase target. e.

0 · Reply

oldhockeyplayerwithteeth Aug. 6 at 8:26 PM

$ADMA Crazy why not a buyout at this stock price. Takeover can lead to possible International expansion and SG-001 looking promising should make ADMA very attractive

0 · Reply

LHBhandy Aug. 6 at 5:07 PM

$ADMA Extremely

0 · Reply

Mr_Maniacal Aug. 6 at 4:58 PM

$ADMA @ncost1 The beauty is there's a nice little sell button you can use... and you can still call a lawyer if you feel slighted... but it's no one else's fault if you overpaid for a stock, and Adam and team have not mislead. I am not sure how you define no growth... they are projecting 2026 at mid-single-digits top line growth with half the year under their belt. The competition in B helps direct their hand to divert more respurces to A... with a higher/moderate product specific moat and better margins... and that product IS growing. This is relatively normal growing pains as other players try to squeeze where they can... but not quite able to touch the flagship. I respect not wanting a one-trick pony... but they are learning new tricks (a few years off still)... ...that aforementioned button remains available for your use...

3 · Reply

michael23 Aug. 6 at 4:08 PM

$ADMA We had to suffer 6 months maybe we get some relief now

0 · Reply

Erod70 Aug. 6 at 1:49 PM

$ADMA legal out of the way, should be at 14-15. Lets see.

0 · Reply

Market Cap	2.29B
Revenue (ttm)	510.17M
Net Income (ttm)	146.93M
EPS (ttm)	N/A
PE Ratio	14.17
Forward PE	13.35
Profit Margin	28.80%
Debt to Equity Ratio	0.50

Volume	3,305,400
Avg Vol	3,185,498
Day's Range	N/A - N/A
Shares Out	231.77M
Stochastic %K	78%
Beta	0.74
Analysts	Sell
Price Target	$15.60